Clinical Trials
Complete title: SC-2015, A Feasibility trial of everolimus (RAD001), an mTOR inhibitor, given in combination with multiagent re-induction in patients with relapsed acute lymphoblastic leukemia (ALL)
Research Study Number | SC-2015 |
Principal Investigator | Todd Cooper |
Phase | I |
In this research study, we are looking to learn more about how Everolimus works in combination with other drugs which are commonly used to treat relapsed acute lymphoblastic leukemia (prednisone, vincristine, PEG-asparaginase, and doxorubicin). The main goal of the study is to evaluate the side effects of this treatment combination in order to determine a safe dose of Everolimus which can be given with these other 4 drugs.
Other eligibility criteria may apply.
Research Study Number | SC-2015 |
Contact | Sini Sreenivas |
Telephone | 206/884-1480 |
Keywords: Leukemia, Acute Lymphoblastic (ALL); Hematologic Malignancies; Leukemia; Lymphoproliferative Disorders; Immunoproliferative Disorders; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Immune System Diseases
Disclaimer: We update this information regularly. However, what you read today may not be completely up to date.